Arvinas, Inc. (ARVN)
NASDAQ·Healthcare·Biotechnology
$10.19
-0.97%
Mkt Cap $669.22M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 24, 2026 | $37.25M | $9.50M | -74.50% | -$0.55 | -$1.10 | -100.00% | — | — |
| Q4 2025 Nov 5, 2025 | $37.26M | $41.90M | +12.44% | -$0.75 | -$0.48 | +36.00% | — | — |
| Q3 2025 Aug 6, 2025 | $25.00M | $22.40M | -10.40% | -$0.87 | -$0.84 | +3.45% | — | — |
| Q2 2025 May 1, 2025 | $42.31M | $188.80M | +346.28% | -$0.86 | $1.14 | +232.56% | — | — |
| Q1 2025 Feb 11, 2025 | $42.53M | $59.20M | +39.19% | -$1.07 | -$0.63 | +41.12% | — | — |
| Q4 2024 Oct 30, 2024 | $59.49M | $102.40M | +72.14% | -$0.88 | -$0.68 | +22.73% | — | — |
| Q3 2024 Jul 30, 2024 | $54.54M | $76.50M | +40.26% | -$0.72 | -$0.49 | +31.94% | — | — |
| Q2 2024 May 7, 2024 | $34.84M | $25.30M | -27.38% | -$1.48 | -$0.97 | +34.46% | — | — |
| Q1 2024 Feb 27, 2024 | $49.30M | $43.10M | -12.58% | -$1.33 | -$2.53 | -90.23% | — | — |
| Q4 2023 Nov 7, 2023 | $40.51M | $34.60M | -14.59% | -$1.52 | -$1.18 | +22.37% | — | — |
| Q3 2023 Aug 8, 2023 | $29.40M | $54.50M | +85.37% | -$1.67 | -$1.25 | +25.15% | — | — |
| Q2 2023 May 5, 2023 | $27.71M | $32.50M | +17.29% | -$1.46 | -$1.54 | -5.48% | — | — |
| Q1 2023 Feb 23, 2023 | $35.72M | $38.00M | +6.39% | -$1.04 | -$1.56 | -50.00% | — | — |
| Q4 2022 Nov 8, 2022 | $34.70M | $30.30M | -12.68% | -$0.98 | -$1.24 | -26.53% | — | — |
| Q3 2022 Aug 4, 2022 | $24.75M | $31.30M | +26.46% | -$1.02 | -$1.32 | -29.41% | — | — |
| Q2 2022 May 5, 2022 | $25.45M | $24.20M | -4.93% | -$0.85 | -$1.20 | -41.18% | — | — |
| Q1 2022 Feb 28, 2022 | $14.14M | $26.30M | +86.02% | -$0.78 | -$1.00 | -28.21% | — | — |
| Q4 2021 Nov 3, 2021 | $245.62M | $9.28M | -96.22% | $2.85 | -$0.94 | -132.98% | — | — |
| Q3 2021 Aug 5, 2021 | $5.54M | $5.54M | +0.01% | -$0.84 | -$1.03 | -22.62% | — | — |
| Q2 2021 May 4, 2021 | $6.91M | $5.54M | -19.84% | -$0.78 | -$0.84 | -7.69% | — | — |